This finding is consistent with previous observational studies demonstrating that psoriasis incidence and severity in obese individuals can be reduced through adiposity-reducing lifestyle interventions54, and with observed improvements in comorbid psoriasis in type 2 diabetes patients treated with weight loss-inducing glucagon-like peptide 1 (GLP-1) receptor agonists55. This evidence concerns the gene GLP1R and psoriasis.